ASC43F

ASC43F is a first-in-class, dual-targeting fixed-dose combination (FDC) tablet developed by Gannex Pharma (a subsidiary of Ascletis Pharma) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). The drug consists of a once-daily single tablet containing 5 mg of ASC41, a thyroid hormone receptor beta (THRβ) agonist, and 15 mg of ASC42, a farnesoid X receptor (FXR) agonist. These two components possess complementary mechanisms of action: THRβ agonists primarily exert anti-metabolic effects to reduce hepatic fat, while FXR agonists provide anti-fibrotic and anti-inflammatory benefits. By combining these modalities, ASC43F is designed to work synergistically to target all major components of MASH, including steatosis, ballooning, inflammation, and fibrosis. Phase I clinical results in healthy subjects have demonstrated that the combination is safe and well-tolerated.